Treatment of Inattention, Overactivity, and Impulsiveness in Autism Spectrum Disorders

Child and Adolescent Psychiatric Clinics of North America

Volumn 17, Issue 4, 2008, Pages 713-738

  Aman, Michael G ^a,b   Farmer, Cristan A ^b   Hollway, Jill ^b   Arnold, L Eugene ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMPHETAMINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; ATOMOXETINE; BUSPIRONE; CHOLINESTERASE INHIBITOR; CLOMIPRAMINE; CLONIDINE; DESIPRAMINE; DEXAMPHETAMINE; FENFLURAMINE; FLUOXETINE; GUANFACINE; HALOPERIDOL; METHYLPHENIDATE; MOOD STABILIZER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; PSYCHOSTIMULANT AGENT; QUETIAPINE; RISPERIDONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; ZIPRASIDONE;

AGGRESSION; AGITATION; ANOREXIA; ATTENTION DEFICIT DISORDER; AUTISM; AUTOMUTILATION; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; DATA ANALYSIS; DELAYED HEART CONDUCTION; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG USE; DRUG WITHDRAWAL; DULLNESS; DYSKINESIA; DYSPHORIA; EMOTIONAL OUTBURST; EXCITABILITY; GENERALIZED TONIC CLONIC SIZURE; GRAND MAL SEIZURE; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPERACTIVITY; IMPULSIVENESS; INSOMNIA; IRRITABILITY; LOW DRUG DOSE; MEDLINE; MOOD DISORDER; PRIORITY JOURNAL; PSYCHOSOCIAL WITHDRAWAL; PSYCINFO; RESTLESSNESS; REVIEW; SADNESS; SIDE EFFECT; STEREOTYPY; SYMPTOM; TACHYCARDIA; TIC; TONIC CLONIC SEIZURE; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; AUTISTIC DISORDER; CHILD; CHILD, PRESCHOOL; CONTROLLED CLINICAL TRIALS AS TOPIC; HUMANS; IMPULSIVE BEHAVIOR; PSYCHOTROPIC DRUGS;

EID: 50449089941     PISSN: 10564993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chc.2008.06.009     Document Type: Review

References (87)

1. Lecavalier L. Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification. J Autism Dev Disord 36 (2006) 1101-1114
2. Aman M.G., Tassé M.J., Rojahn J., et al. The Nisonger CBRF: a child behavior rating form for children with developmental disabilities. Res Dev Disabil 17 (1996) 41-57
3. Arnold L.E., Gadow K.D., Pearson D.A., et al. Stimulants. In: Reiss S., and Aman M.G. (Eds). Psychotropic medication and developmental disabilities: the international consensus handbook (1998), Ohio State University Nisonger Center, Columbus (OH) 229-257
4. Aman M.G., Buican B., and Arnold L.E. Methylphenidate treatment in children with low IQ and ADHD: analysis of three aggregated studies. J Child Adolesc Psychopharmacol 13 (2003) 27-38
5. Pearson D., Lane D., Santos C., et al. Effects of methylphenidate treatment in children with mental retardation and ADHD: individual variation in medication response. J Am Acad Child Adolesc Psychiatry 43 (2004) 686-698
6. Campbell M., Fish B., David R., et al. Response to tri-iodothyronine and dextroamphetamine: a study of preschool schizophrenic children. J Autism Child Schizophr 2 (1972) 343-358
7. Campbell M., Small A.M., Collins P.J., et al. Levodopa and levoamphetamine:a crossover study in young schizophrenic children. Curr Ther Res Clin Exp 19 (1976) 70-86
8. Connor D.F. Psychostimulants in attention deficit hyperactivity attention deficit disorder: theoretical and practical issues for the community practitioner. In: Gozal D., and Molfese D.L. (Eds). Attention deficit hyperactivity disorder: from genes to patients (2007), Humana Press, Totowa (NJ) 487-528
9. Hoshino Y., Kumashiro H., Kaneko M., et al. Effects of methylphenidate on early infantile autism and its relation to serum serotonin levels. Folia Psychiatrica et Neurologica Japonica 3 4 (1977) 605-614
10. Birmaher B., Quintana H., and Greenhill L.L. Methylphenidate treatment of hyperactive autistic children. J Am Acad Child Adolesc Psychiatry 27 (1988) 248-251
11. Di Martino A., Melis G., Cianchetti C., et al. Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study. J Child Adolesc Psychopharmacol 14 (2004) 207-218
12. Quintana H., Birmaher B., Stedge D., et al. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord 25 (1995) 283-294
13. Handen B.L., Johnson C.R., and Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 30 (2000) 245-255
14. Santosh P.J., Baird G., Pityaratstian N., et al. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study. Child Care Hlth Dev 32 (2006) 575-583
15. Guy W. ECDEU assessment manual of psychopharmacology (NIMH Publication 76-338) (1976), Department of Health, Education, and Welfare; NIMH, Washington, DC
16. Research Units on Pediatric Psychopharmacology Autism Network. A randomized, double-blind, placebo-controlled, crossover trial of methylphenidate in children with hyperactivity associated with pervasive developmental disorders. Arch Gen Psychiatry 62 (2005) 1266-1274
17. Posey D.J., Aman M.G., McCracken J.T., et al. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. Biol Psychiatry 61 (2007) 538-544
18. Aman M.G., Singh N., Stewart A., et al. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 89 (1985) 485-491
19. Aman M.G., Singh N.N., Stewart A.W., et al. Psychometric characteristics of the Aberrant Behavior Checklist. Am J Ment Defic 89 (1985) 492-502
20. Swanson J. School-based assessments and interventions for ADD students (1992), KC Publishing, Irvine (CA)
21. Jou R., Handen B., and Hardan A. Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol 15 (2005) 325-330
22. Goyette C., Conners C., and Ulrich R. Normative data on revised Conners Parent And Teacher Rating Scales. J Abnorm Child Psychol 6 (1978) 221-236
23. Troost P., Steenhuis M., Tuynman H., et al. Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study. J Child Adolesc Psychopharmacol 16 (2006) 611-619
24. DuPaul G., Power T., Anastopoulos A., et al. ADHD rating scale-IV: checklists, norms, and clinical interpretations (1998), The Guilford Press, New York
25. Posey D., Wiegand R., Wilkerson J., et al. Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol 16 (2006) 599-610
26. Conners C. Conners' continuous performance test-II (2000), Multi Health Systems, North Tonawanda (NY)
27. Spencer T., Biederman J., Wilens T., et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 155 (1998) 693-695
28. Arnold L., Aman M., Cook A., et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 45 (2006) 1196-1205
29. Michelson D., Faires D., Wernicke J., et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108 (2001) 1-9
30. Michelson D., Allen A., Busner J., et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159 (2002) 1896-1901
31. Sutton V, Milton D, Ruff D, et al. Efficacy of atomoxetine treatment for children and adolescents with attention-deficit/hyperactivity disorder. Paper presented at the 51st Annual Meeting American Academy of Child and Adolescent Psychiatry. Washington, DC: 2004, October.
32. Spencer T., Biederman J., Heiligenstein J., et al. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 11 (2001) 251-265
33. Waizer J., Polizos P., Hoffman S.P., et al. A single-blind evaluation of thiothixene with outpatient schizophrenic children. J Autism Child Schizophr 2 (1972) 378-386
34. Anderson L.T., Campbell M., Grega D.M., et al. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 141 (1984) 1195-1202
35. Fish B. Children's psychiatric rating scale. Psychopharmacol Bull 21 (1985) 753-770
36. Campbell M., Armenteros J.L., Malone R.P., et al. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 36 (1997) 835-843
37. Bezchlibnyk-Butler K.Z., and Jefferies J.J. Clinical handbook of psychotropic drugs. 15th edition (2005), Hogrefe & Huber Publishers, Ashland (OH)
38. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism for serious behavioral problems. N Engl J Med 347 (2002) 314-321
39. Shea S., Turgay A., Carroll A., et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114 (2004) 634-641
40. Hellings J.A., Zarcone J.R., and Reese R.M. A crossover study of risperidone in children, adolescents and adults with mental retardation. J Autism Dev Disord 36 (2006) 401-411
41. Troost P.W., Althaus M., and Lahius B.E. Neuropsychological effects of risperidone in children with pervasive developmental disorders: a blinded discontinuation study. J Child Adolesc Psychopharmacol 16 (2006) 561-573
42. Troost P.W., Lahius B.E., and Steenhuis M.P. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry 44 (2005) 1137-1144
43. Corson A.H., Barkenbus J.E., Posey D.J., et al. A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. J Clin Psychiatry 65 (2004) 1531-1536
44. Hardan A.Y., Jou R.J., and Handen B.L. Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders. J Autism Dev Disord 35 (2005) 387-391
45. Malone R.P., Delaney M.A., Hyman S.B., et al. Ziprasidone in adolescents with autism: an open-label pilot study. J Child Adolesc Psychopharmacol 17 (2007) 779-790
46. Valicenti-McDermott M.R., and Demb H. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. J Child Adolesc Psychopharmacol 16 (2006) 549-560
47. Fankhauser M.P., Karumanchi V.C., German M.L., et al. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 53 (1991) 77-82
48. Jaselskis C.A., Cook Jr. E.H., Fletcher K.E., et al. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 12 (1992) 322-327
49. Posey D.J., Puntney J.I., Sasher T.M., et al. Guanfacine treatment of hyperactivity in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol 14 (2004) 233-241
50. Scahill L., Aman M.G., McDougle C.J., et al. A prospective open-trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol 16 (2006) 589-598
51. Geller B., Reising D., Leonard H., et al. Critical review of tricyclic antidepressant use in children and adolescents. J Am Child Adolesc Psychiatry 38 (1999) 513-516
52. Gordon C., Rapoport J., Hamburger S., et al. Differential response of seven subjects with autistic disorder to clomipramine and desipramine. Am J Psychiatry 149 (1992) 363-366
53. Gordon C., State R., Nelson J., et al. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 50 (1993) 441-447
54. Cook E.H., Rowlett R., Jaselskis C., et al. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 31 (1992) 739-745
55. Todd R. Fluoxetine in autism. Am J Psychiatry 148 (1991) 1089
56. Fatemi S., Realmuto G., Khan L., et al. Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial. J Autism Dev Disord 28 (1998) 303-307
57. Hollander E., Kaplan A., Cartwright C., et al. Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report. J Child Neurol 15 (2000) 132-135
58. Werry J., and Aman M.G. Anxiolytics, sedatives, and miscellaneous drugs. In: Werry J., and Aman M.G. (Eds). Practitioner's guide to psychoactive drugs for children and adolescents. 2nd edition (1999), Plenum Medical Book Company, New York 433-469
59. Realmuto G.M., August G.J., and Garfinkel B.D. Clinical effect of buspirone in autistic children. J Clin Psychopharmacol 9 (1989) 122-125
60. Conners C. A teacher rating scale for use in drug studies with children. Am J Psychiatry 126 (1969) 884-888
61. McCormick L. Treatment with buspirone in a child with autism. Arch Fam Med 6 4 (1997) 368-370
62. Marrosu F., Marrosu G., Rachel M., et al. Paradoxical reactions elicited by diazepam in children with classic autism. Funct Neurol 3 (1987) 355-361
63. Perry E.K., Lee M.L., Martin-Ruiz C.M., et al. Cholinergic activity in autism: abnormalities in the cerebral cortex and basal forebrain. Am J Psychiatry 158 (2001) 1058-1066
64. Lee M., Martin-Ruiz C., Graham A., et al. Nicotinic receptor abnormalities in the cerebellar cortex in autism. Brain 125 (2002) 1483-1495
65. Hardan A.Y., and Handen B.L. A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 12 (2002) 237-241
66. Neiderhofer H. Galantamine may be effective in treating autistic disorder. [letters]. BMJ 325 (2002) 1422-1423
67. Nicolson R., Craven-Thuss B., and Smith J. A prospective, open-label trial of galantamine in autistic disorder. J Child Adolesc Psychopharmacol 16 (2006) 621-629
68. Chez M.G., Aimonovich M., Buchanan T., et al. Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate. J Child Neurol 19 3 (2004) 165-169
69. Conners C. Conners' rating scales-revised, technical manual (1997), Multi-Health Systems, Toronto
70. King B.H., Wright D.M., Handen B.L., et al. Double-blind placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry 40 (2001) 658-665
71. Carlsson M. Hypothesis: Is infantile autism a hypoglutamatergic disorder? Relevance of glutamate-serotonin interactions for pharmacotherapy. J Neural Transm 105 (1998) 525-535
72. Lappalainen R., and Riikonen R. High levels of cerebrospinal fluid in Rett syndrome. Pediatr Neurol 15 (1996) 213-216
73. Owley T., Salt J., Guter S., et al. A prospective, open-label, trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. J Child Adolesc Psychopharmacol 16 (2006) 517-524
74. Erickson C.A., Posey D.J., Stigler K.A., et al. A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl) 191 (2007) 141-147
75. Hollander E., Dolgoff-Kaspar R., Cartwright C., et al. An open trial of divalproex sodium in autistic disorder spectrum disorders. J Clin Psychiatry 62 (2001) 530-534
76. Uvebrant P., and Bauziene R. Intractable epilepsy in children: the efficacy of lamotrigine treatment including nonsiezure-related benefits. Neuropediatrics 25 (1994) 284-289
77. Belsito K., Law P., Kirk K., et al. Lamotrigine therapy for autistic disorder: a randomized double-blind, placebo-controlled trial. J Autism Dev Disord 31 (2001) 175-181
78. Krug D.A., Arick J., and Almond P. Autism behavior checklist record form (1993), PRO-ED, Austin (TX)
79. Hardan A., Jou R., and Handen B. A retrospective assessment of topiramate in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol 14 (2004) 426-432
80. Campbell M., Overall J.E., Small A.M., et al. Naltrexone in autistic children: an acute open dose range tolerance trial. J Am Acad Child Adolesc Psychiatry 28 (1989) 200-206
81. Campbell M., Anderson L.T., Small A.M., et al. Naltrexone in autistic children: behavioral symptoms and attentional learning. J Am Acad Child Adolesc Psychiatry 32 (1993) 1283-1291
82. Kolmen B.K., Feldman H., Handen B.L., et al. Naltrexone in young autistic children: a double-blind placebo-controlled crossover study. J Am Acad Child Adolesc Psychiatry 34 (1995) 223-231
83. Willemsen-Swinkles S.H., Buitelaar J.K., Weijnen F.G., et al. Placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry Res 58 (1995) 203-215
84. Willemsen-Swinkles S.H., Buitelaar J.K., and van Engeland H. The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo controlled crossover study. Biol Psychiatry 39 (1996) 1023-1031
85. Kolmen B.K., Feldman H., Handen B.L., et al. Naltrexone in young autistic children: replication study and learning measures. J Am Acad Child Adolesc Psychiatry 36 (1997) 1570-1578
86. Willemsen-Swinkles S.H., Builtelaar J.K., van Berkelaer-Onnes I.A., et al. Brief report: six months continuation treatment in naltrexone-responsive children with autism: a double blind placebo-controlled crossover study. J Autism Dev Disord 29 (1999) 167-169
87. Aman M.G., and Langworthy K.S. Pharmacotherapy for hyperactivity in children with autism and other pervasive developmental disorders. J Autism Dev Disord 30 (2000) 451-459